Acute psychotic disorders treated with 5% zuclopenthixol acetate in 'Viscoleo' ('Cisordinol-Acutard'), a global assessment of the clinical effect: an open multi-centre study.

Abstract

In an open clinical multi-centre trial carried out in five Danish psychiatric departments, patients suffering from acute psychosis including mania or exacerbation of chronic psychosis were given injections of 5% zuclopenthixol acetate in 'Viscoleo'. The object of the trial was to evaluate the treatment by means of a global assessment of the severity of the psychosis, the therapeutic effect and the side-effects. The results showed that the treatment was rapidly effective in reducing the severity of psychotic symptoms combined with an advantageous unspecific sedation. The side-effect profile was similar to that after other neuroleptics. Special attention should be paid, however, to a possible occurrence of acute dystonia which was observed particularly in young men with acute psychosis.

• Authors: A C Løwert, E M Rasmussen, R Holm, F Almbjerg, H Calberg, A Joensen, M Nimb, H Baden, E Andersen, T Westergård
• Journal: Pharmatherapeutica (Pharmatherapeutica) Vol. 5 Issue 6 Pg. 380-6 ( 1989) ISSN: 0308-051X [Print] England
• PMID: 2687895 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Thioxanthenes
• Clopenthixol

Topics

• Acute Disease
• Adult
• Bipolar Disorder (chemically induced)
• Clinical Trials as Topic
• Clopenthixol (adverse effects, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Multicenter Studies as Topic
• Psychotic Disorders (drug therapy)
• Thioxanthenes (therapeutic use)